GlassScriptPhysician profile
Sandra M Quezada
NPI 1609911387
$26,643.71
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $966 · 2023: $6,591 · 2024: $4,498 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $2,432 · Food and Beverage: $2,347 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,850.00 |
| Travel and Lodging | $2,431.50 |
| Food and Beverage | $2,347.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $11,315.43 | 2024-2025 | Tremfya |
| Pfizer INC. | $6,543.46 | 2025 | |
| Eli Lilly and Company | $5,939.61 | 2023 | |
| Janssen Biotech, INC. | $1,514.05 | 2022-2025 | Tremfya, Stelara |
| Abbvie INC. | $543.06 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $313.28 | 2024 | |
| Celgene Corporation | $201.50 | 2022-2023 | Zeposia |
| Janssen Research & Development, LLC | $122.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.03 | 2023 | Entyvio |
| Lilly USA, LLC | $60.91 | 2025 | Omvoh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Quezada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.